fda glp-1 warning letters november 2025 Pharmaceutical Advertising Regulations Societies take stand against off-brand

Behavioral health referrals

Key points: GLP-1s (glucagon-like peptide-1 receptor agonists) support type 2 diabetes by reducing appetite and supporting weight loss alongside their effects on the pancreas GLP-1-assisted programmes lead to a clinically significant weight loss of 10% or more, which can significantly reduce complications associated with obesity Combining semaglutide with lifestyle interventions leads to significantly more weight loss than lifestyle interventions alone, with 87% of participants losing more than 10% of their body weight Semaglutide is more effective at supporting weight loss than liraglutide Tirzepatide is more effective than semaglutide at reducing weight, with all three doses of tirzepatide leading to more significant weight loss than 1mg of semaglutide The higher doses of tirzepatide (10mg and 15mg) might reduce weight by 5.15kg more than 2mg of semaglutide, while there appears to be no difference between 5mg of tirzepatide and 2mg of semaglutide 3) Side effects and safety All medications have possible side effects, particularly if you live with other health conditions

Currently, there is no established direct link between Zepbound and decreased sexual desire in FDA prescribing information or clinical trial data

Sex Drive Some researchers have begun to investigate how GLP-1 drugs might affect your libido, or sex drive

At FPA Womens Health, were seeing more women ask how GLP-1 medications may affect birth control, fertility, and pregnancy planning

GLP-1 with its unique mechanism of action